Icon appoints new Group Director of Research

Icon Writers / 26 Jul, 2023

Icon is excited to announce the appointment of Dr Craig Gedye as the new Group Director of Research for Medical Oncology and Haematology.

Dr Gedye brings with him a wealth of experience and expertise in cancer research, making him an invaluable addition to our strong clinical leadership team. With an extensive background in both public and private hospitals in Australia, New Zealand and Canada, Dr Gedye has held key leadership roles that have significantly contributed to the advancement of cancer care globally.  

His accomplishments include serving as the Associate Director of the HMRI Clinical Trials Unit, Clinical Research Director for the NSW Health Statewide Biobank, and Chair of the ANZUP Cancer Trials Group’s Renal Cancer Subcommittee. Additionally, he holds the position of Conjoint Associate Professor at the University of Newcastle. 

Icon Group CEO, Mark Middleton OAM says this appointment further strengthens Icon’s clinician-led values and commitment to the future of cancer care.  

“Craig is an incredible win for Icon and his impressive reputation will no doubt bring new research opportunities and growth for our teams in Australia and internationally,” said Mark. 

“We’re really proud of our clinical leadership and our 300 plus doctor network committed to advancing cancer care and increasing access to new and emerging treatments.” 

Throughout his career, Dr Gedye has been dedicated to exceptional patient care and advancing medicine through cutting-edge research and has published over 80 manuscripts. His extensive expertise spans the entire research spectrum, encompassing patient experience, clinical trials, and translational science. 

 Dr Gedye’s appointment follows the retirement of former Director of Research, Dr John Bashford earlier this year. Dr Bashford has been instrumental in establishing Icon’s clinical excellence in research.  

“Craig’s dedication to research will confidently drive forward John’s legacy and evolve Icon’s research capabilities,” said Mark.  

“We’re the largest private provider of cancer clinical trials in Australia and we have expanded this proven model into our Singapore network with a vision to deliver more cutting-edge research to more people. 

“Research is part of Icon’s DNA and critical to delivering holistic cancer care. Craig’s appointment marks the next chapter of growth and cements our position as leaders in oncology trials.”

Dr Gedye join’s Icon’s research leadership cohort of Executive Manager, Sophie Mepham, and Group Director of Research for Radiation Medicine and Theranostics, Dr Jonathan Ramsay and is excited to join a team helping to shape future cancer care outcomes. 

 “Icon has an incredibly impressive research and clinical governance framework with a proven ability to conduct an expansive trials program safely and efficiently,” said Dr Gedye.  

“I’m looking forward to help lead Icon’s research strategy alongside a well-established clinical team and provide clinical trial opportunities for our patients globally and improve quality of life for people and families, and communities today and into the future.” 

Icon delivers trials across Phase I – IV including an extensive Investigator Initiated Trials program, and has capability in medical oncology, haematology, radiation medicine, and theranostics.

Our research services here. Or view our 2022 Annual Research Report 

View all News


Contact us